Steeg et al. [3] demonstrated the involvement of HER2 signaling in outgrowth of breast cancer-derived experimental brain metastases, but not in initiation of these lesions [10]; outgrowth therefore appears to be the key process to capture in a model used to evaluate the effects of HER2 inhibition. The gene discussed is ERBB2; the disease is breast cancer.